Surescripts to Present New Data on Opportunities to Expand Access & Fill Gaps in Primary Care and More at NCPDP 2023 Annual Technology & Business Conference

Surescripts, the nation’s leading health information network, will lead two sessions at the National Council for Prescription Drug Programs (NCPDP) Annual Technology & Business Conference on May 9, 2023, on Opportunities to Expand Access & Fill Gaps in Primary Care and Improving Sig Clarity: Tools…

Read MoreSurescripts to Present New Data on Opportunities to Expand Access & Fill Gaps in Primary Care and More at NCPDP 2023 Annual Technology & Business Conference

Nuvo Group Ltd., A Leading FDA-Cleared Innovator in Pregnancy Care, and LAMF Global Ventures Corp I, Led by Chairman Jeffrey Soros and CEO Simon Horsman, Announce Intent to List Nuvo on Nasdaq Through a Business Combination

Nuvo Group Ltd. (“Nuvo” or “the Company”), the creators of INVU by Nuvo™, an FDA-cleared remote pregnancy monitoring platform, and LAMF Global Ventures Corp I (NASDAQ: LGVC) (“LAMF”), a special purpose acquisition company (“SPAC”), today announced that they have entered…

Read MoreNuvo Group Ltd., A Leading FDA-Cleared Innovator in Pregnancy Care, and LAMF Global Ventures Corp I, Led by Chairman Jeffrey Soros and CEO Simon Horsman, Announce Intent to List Nuvo on Nasdaq Through a Business Combination

LE SYSTÈME DE SGC EN TEMPS RÉEL (SGCtr) DEXCOM G6 EST MAINTENANT COUVERT PAR LE PROGRAMME DES SSNA POUR TOUS LES CLIENTS ATTEINTS DE DIABÈTE ADMISSIBLES QUI PRENNENT DE L’INSULINE

Dexcom, Inc. (NASDAQ : DXCM), un chef de file à l’échelle internationale dans le domaine de la surveillance du glucose en continu (SGC) et en temps réel pour les personnes atteintes de diabète, se réjouit de l’élargissement progressif de la…

Read MoreLE SYSTÈME DE SGC EN TEMPS RÉEL (SGCtr) DEXCOM G6 EST MAINTENANT COUVERT PAR LE PROGRAMME DES SSNA POUR TOUS LES CLIENTS ATTEINTS DE DIABÈTE ADMISSIBLES QUI PRENNENT DE L’INSULINE

Global AI-Enabled Medical Imaging Solutions Market Research Report 2023: An $18.356 Billion Market by 2032, Growing at a CAGR of 25.76% – ResearchAndMarkets.com

The global AI-enabled medical imaging solutions market was valued at $1,854.5 million in 2022 and is anticipated to reach $18,356.5 million by 2032, witnessing a CAGR of 25.76% during the forecast period 2022-2032. The growth in the global AI-enabled medical…

Read MoreGlobal AI-Enabled Medical Imaging Solutions Market Research Report 2023: An $18.356 Billion Market by 2032, Growing at a CAGR of 25.76% – ResearchAndMarkets.com

Die Stallergenes Greer Foundation fördert Innovation und Präzisionsmedizin auf dem Gebiet der Allergien

Stallergenes Greer, ein biopharmazeutisches Unternehmen, das sich auf die Erforschung, Diagnose und Behandlung von Allergien der Atemwege spezialisiert hat, freut sich, seine strategische Ausrichtung für die Stallergenes Greer Foundation bekannt zu geben. Die unter der Schirmherrschaft der Fondation de France…

Read MoreDie Stallergenes Greer Foundation fördert Innovation und Präzisionsmedizin auf dem Gebiet der Allergien

Acuamark Diagnostics Welcomes Giulia Kennedy, Former Chief Scientific and Chief Medical Officer of Veracyte, to its Board of Directors

Acuamark Diagnostics has appointed Giulia Kennedy, Ph.D., formerly global chief scientific officer and chief medical officer of diagnostics company Veracyte, to its board of directors. “With sharp intellect, deep humanity and decades of in-depth genomic diagnostic development, company building, and commercialization experience, she…

Read MoreAcuamark Diagnostics Welcomes Giulia Kennedy, Former Chief Scientific and Chief Medical Officer of Veracyte, to its Board of Directors